Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | GFER | P55789 | 2/20 | 0.32 |
| ▸ | DRD2 | P14416 | 2/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21389222 | 0.85 | DRD2 (0.41) | AKT1CACNA1HALDH1A1GFERDRD2 | |
| SCHEMBL12590064 | 0.82 | HTT (0.37) | HTTALDH1A1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL19978666 | 0.80 | HTT (0.39) | HTTALDH1A1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL700572 | 0.80 | AKT1 (0.51) | AKT1HTTALDH1A1GFERDRD2 | |
| SCHEMBL16309339 | 0.76 | MTNR1A (0.46) | LMNASMN1; SMN2 | |
| SCHEMBL13950300 | 0.76 | SMN1; SMN2 (0.40) | HTTALDH1A1SMN1; SMN2EPHX1 | |
| SCHEMBL20330624 | 0.75 | HPGD (0.36) | HTTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL12799289 | 0.75 | AKT1 (0.38) | AKT1HTTALDH1A1GFERDRD2 | |
| SCHEMBL18471059 | 0.75 | HDAC6 (0.34) | HTTLMNASMN1; SMN2 | |
| SCHEMBL15934066 | 0.73 | MTNR1A (0.41) | HTTALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8487080-B2 | Fluorine-labeled compounds | GENERAL ELECTRIC COMPANY (US) | 2013-07-16 | — | — | US | disclosed |
| US-20110160430-A1 | FLUORINE-LABELED COMPOUNDS | GENERAL ELECTRIC COMPANY (US) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160430-A1 | FLUORINE-LABELED COMPOUNDS | PFAS, DHFR, PAICS | AKT1 4279/4885CACNA1H 4835/4885HTT 1849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.